Breaking the Barriers of Therapy Resistance: Harnessing Ferroptosis for Effective Hepatocellular Carcinoma Therapy

References

• Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77(6):1598–1606. doi:10.1016/j.jhep.2022.08.021
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. doi:10.1038/s41572-020-00240-3
   PubMed Web of Science ®Google Scholar
• Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38(36):4317–4345. doi:10.1200/JCO.20.02672
   PubMed Web of Science ®Google Scholar
• Deng H, Kan A, Lyu N, et al. Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma. J Immunother Cancer. 2021;9(6):e002305. doi:10.1136/jitc-2020-002305
   PubMed Web of Science ®Google Scholar
• Wang T, Qin Z-Y, Wen L-Z, et al. Epigenetic restriction of Hippo signaling by MORC2 underlies stemness of hepatocellular carcinoma cells. Cell Death Differ. 2018;25(12):2086–2100. doi:10.1038/s41418-018-0095-6
   PubMed Web of Science ®Google Scholar
• Di Giacomo S, Briz O, Monte MJ, et al. Chemosensitization of hepatocellular carcinoma cells to sorafenib by β-caryophyllene oxide-induced inhibition of ABC export pumps. Arch Toxicol. 2019;93(3):623–634. doi:10.1007/s00204-019-02395-9
   PubMed Web of Science ®Google Scholar
• Song Z, Liu T, Chen J, et al. HIF-1α-induced RIT1 promotes liver cancer growth and metastasis and its deficiency increases sensitivity to sorafenib. Cancer Lett. 2019;460:96–107. doi:10.1016/j.canlet.2019.06.016
   PubMed Web of Science ®Google Scholar
• Dong N, Shi X, Wang S, et al. M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma. Br J Cancer. 2019;121(1):22–33. doi:10.1038/s41416-019-0482-x
   PubMed Web of Science ®Google Scholar
• Tang D, Chen X, Kang R, Kroemer G. Ferroptosis: molecular mechanisms and health implications. Cell Res. 2021;31(2):107–125. doi:10.1038/s41422-020-00441-1
   PubMed Web of Science ®Google Scholar
• Shang Y, Luo M, Yao F, Wang S, Yuan Z, Yang Y. Ceruloplasmin suppresses ferroptosis by regulating iron homeostasis in hepatocellular carcinoma cells. Cell Signal. 2020;72:109633. doi:10.1016/j.cellsig.2020.109633
   PubMed Web of Science ®Google Scholar
• Zhu G, Murshed A, Li H, et al. O-GlcNAcylation enhances sensitivity to RSL3-induced ferroptosis via the YAP/TFRC pathway in liver cancer. Cell Death Discov. 2021;7(1):83. doi:10.1038/s41420-021-00468-2
   PubMed Web of Science ®Google Scholar
• Zhao Y, Li M, Yao X, et al. HCAR1/MCT1 regulates tumor ferroptosis through the lactate-mediated AMPK-SCD1 activity and its therapeutic implications. Cell Rep. 2020;33(10):108487. doi:10.1016/j.celrep.2020.108487
   PubMed Web of Science ®Google Scholar
• Wang Q, Guo Y, Wang W, et al. RNA binding protein DAZAP1 promotes HCC progression and regulates ferroptosis by interacting with SLC7A11 mRNA. Exp Cell Res. 2021;399(1):112453. doi:10.1016/j.yexcr.2020.112453
   PubMed Web of Science ®Google Scholar
• Yao F, Deng Y, Zhao Y, et al. A targetable LIFR-NF-ΰB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nat Commun. 2021;12(1):7333. doi:10.1038/s41467-021-27452-9
   PubMed Web of Science ®Google Scholar
• Romualdo GR, Leroy K, Costa C, et al. In vivo and in vitro models of hepatocellular carcinoma: current strategies for translational modeling. Cancers. 2021;13(21):5583. doi:10.3390/cancers13215583
   PubMed Web of Science ®Google Scholar
• Sanchez-Martin A, Sanchon-Sanchez P, Romero MR, Marin JJG, Briz O. Impact of tumor suppressor genes inactivation on the multidrug resistance phenotype of hepatocellular carcinoma cells. Biomed Pharmacother. 2023;165:115209. doi:10.1016/j.biopha.2023.115209
   PubMed Web of Science ®Google Scholar
• Zhao S, Zhang Y, Lu X, et al. CDC20 regulates the cell proliferation and radiosensitivity of P53 mutant HCC cells through the Bcl-2/Bax pathway. Int J Biol Sci. 2021;17(13):3608–3621. doi:10.7150/ijbs.64003
   PubMed Web of Science ®Google Scholar
• Tang C, Qiu S, Mou W, Xu J, Wang P. Excessive activation of HOXB13/PIMREG axis promotes hepatocellular carcinoma progression and drug resistance. Biochem Biophys Res Commun. 2022;623:81–88. doi:10.1016/j.bbrc.2022.07.066
   PubMed Web of Science ®Google Scholar
• Marin JJG, Macias RIR, Monte MJ, et al. Molecular bases of drug resistance in hepatocellular carcinoma. Cancers. 2020;12(6):1663.
   PubMed Web of Science ®Google Scholar
• Buonanno M, De toledo SM, Pain D, Azzam EI. Long-term consequences of radiation-induced bystander effects depend on radiation quality and dose and correlate with oxidative stress. Radiat Res. 2011;175(4):405–415. doi:10.1667/RR2461.1
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao H, Yu J, et al. MiR-320b/RAD21 axis affects hepatocellular carcinoma radiosensitivity to ionizing radiation treatment through DNA damage repair signaling. Cancer Sci. 2021;112(2):575–588. doi:10.1111/cas.14751
   PubMed Web of Science ®Google Scholar
• Liao J, Yi Y, Yue X, et al. Methyltransferase 1 is required for nonhomologous end-joining repair and renders hepatocellular carcinoma resistant to radiotherapy. Hepatology. 2023;77(6):1896–1910. doi:10.1002/hep.32615
   PubMed Web of Science ®Google Scholar
• Ladd AD, Duarte S, Sahin I, Zarrinpar A. Mechanisms of drug resistance in HCC. Hepatology. 2023;79(4):926–940. doi:10.1097/HEP.0000000000000237
   PubMed Web of Science ®Google Scholar
• Zheng T, Yin D, Lu Z, et al. Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma. Mol Cancer. 2014;13(1):133. doi:10.1186/1476-4598-13-133
   PubMedGoogle Scholar
• Qian B, Che L, Du Z-B, et al. Protein phosphatase 2A-B55β mediated mitochondrial p-GPX4 dephosphorylation promoted sorafenib-induced ferroptosis in hepatocellular carcinoma via regulating p53 retrograde signaling. Theranostics. 2023;13(12):4288–4302. doi:10.7150/thno.82132
   PubMed Web of Science ®Google Scholar
• Lee JH, Suh JH, Kang HJ, et al. Tonicity-responsive enhancer-binding protein promotes stemness of liver cancer and cisplatin resistance. EBioMedicine. 2020;58:102926. doi:10.1016/j.ebiom.2020.102926
   PubMed Web of Science ®Google Scholar
• Chen C, Wang Z, Ding Y, Qin Y. Tumor microenvironment-mediated immune evasion in hepatocellular carcinoma. Front Immunol. 2023;14:1133308. doi:10.3389/fimmu.2023.1133308
   PubMedGoogle Scholar
• Zhang S, Yuan L, Danilova L, et al. Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence. Genome Med. 2023;15(1):72. doi:10.1186/s13073-023-01218-y
   PubMed Web of Science ®Google Scholar
• Xing R, Gao J, Cui Q, Wang Q. Strategies to improve the antitumor effect of immunotherapy for hepatocellular carcinoma. Front Immunol. 2021;12:783236. doi:10.3389/fimmu.2021.783236
   PubMed Web of Science ®Google Scholar
• Zhou Z, Li X, Yang G, et al. Targeting β-catenin and PD-L1 simultaneously by a racemic supramolecular peptide for the potent immunotherapy of hepatocellular carcinoma. Theranostics. 2023;13(10):3371–3386. doi:10.7150/thno.83377
   PubMed Web of Science ®Google Scholar
• Chen S, Du Y, Guan X-Y, Yan Q. The current status of tumor microenvironment and cancer stem cells in sorafenib resistance of hepatocellular carcinoma. Front Oncol. 2023;13:1204513. doi:10.3389/fonc.2023.1204513
   PubMed Web of Science ®Google Scholar
• Wang J, Yu H, Dong W, et al. N6-methyladenosine-mediated up-regulation of FZD10 regulates liver cancer stem cells’ properties and lenvatinib resistance through WNT/β-catenin and hippo signaling pathways. Gastroenterology. 2023;164(6):990–1005.
   PubMed Web of Science ®Google Scholar
• Zhang D, Wu F, Song J, et al. A role for the NPM1/PTPN14/YAP axis in mediating hypoxia-induced chemoresistance to sorafenib in hepatocellular carcinoma. Cancer Cell Int. 2022;22(1):65. doi:10.1186/s12935-022-02479-0
   PubMed Web of Science ®Google Scholar
• Liao Y, Yang Y, Pan D, et al. HSP90α mediates sorafenib resistance in human hepatocellular carcinoma by necroptosis inhibition under hypoxia. Cancers. 2021;13(2):243. doi:10.3390/cancers13020243
   PubMed Web of Science ®Google Scholar
• Bamodu OA, Chang H-L, Ong J-R, Lee W-H, Yeh C-T, Tsai J-T. Elevated PDK1 expression drives PI3K/AKT/MTOR signaling promotes radiation-resistant and dedifferentiated phenotype of hepatocellular carcinoma. Cells. 2020;9(3):746. doi:10.3390/cells9030746
   PubMed Web of Science ®Google Scholar
• Raju B, Choudhary S, Narendra G, Verma H, Silakari O. Molecular modeling approaches to address drug-metabolizing enzymes (DMEs) mediated chemoresistance: a review. Drug Metab Rev. 2021;53(1):45–75. doi:10.1080/03602532.2021.1874406
   PubMed Web of Science ®Google Scholar
• Giannitrapani L, Di Gaudio F, Cervello M, et al. Genetic biomarkers of sorafenib response in patients with hepatocellular carcinoma. Int J Mol Sci. 2024;25(4):2197. doi:10.3390/ijms25042197
   PubMed Web of Science ®Google Scholar
• Caputo TM, Cusano AM, Principe S, et al. Sorafenib-loaded PLGA carriers for enhanced drug delivery and cellular uptake in liver cancer cells. Int J Nanomed. 2023;18:4121–4142. doi:10.2147/IJN.S415968
   PubMed Web of Science ®Google Scholar
• Wei J, Liu R, Zhang J, et al. Baicalin enhanced oral bioavailability of sorafenib in rats by inducing intestine absorption. Front Pharmacol. 2021;12:761763. doi:10.3389/fphar.2021.761763
   PubMed Web of Science ®Google Scholar
• Guo R, Lu F, Lin J, Fu C, Liu M, Yang S. Multi-b-value DWI to evaluate the synergistic antiproliferation and anti-heterogeneity effects of bufalin plus sorafenib in an orthotopic HCC model. Eur Radiol Exp. 2024;8(1):43. doi:10.1186/s41747-024-00448-y
   PubMedGoogle Scholar
• Da X, Mo J, Li Q, et al. Targeted co-delivery of PD-L1 monoclonal antibody and sorafenib to circulating tumor cells via platelet-functionalized nanocarriers. Biochem Biophys Res Commun. 2023;671:335–342. doi:10.1016/j.bbrc.2023.05.124
   PubMed Web of Science ®Google Scholar
• Rigalli JP, Ciriaci N, Arias A, et al. Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity. PLoS One. 2015;10(3):e0119502. doi:10.1371/journal.pone.0119502
   PubMed Web of Science ®Google Scholar
• Yu G, Chen X, Chen S, Ye W, Hou K, Liang M. Arsenic trioxide reduces chemo-resistance to 5-fluorouracil and cisplatin in HBx-HepG2 cells via complex mechanisms. Cancer Cell Int. 2015;15(1):116. doi:10.1186/s12935-015-0269-y
   PubMedGoogle Scholar
• Kong J, Qiu Y, Li Y, Zhang H, Wang W. TGF-β1 elevates P-gp and BCRP in hepatocellular carcinoma through HOTAIR/miR-145 axis. Biopharm Drug Dispos. 2019;40(2):70–80. doi:10.1002/bdd.2172
   PubMed Web of Science ®Google Scholar
• Lai S-C, Y-t S, Chi -C-C, et al. DNMT3b/OCT4 expression confers sorafenib resistance and poor prognosis of hepatocellular carcinoma through IL-6/STAT3 regulation. J Exp Clin Cancer Res. 2019;38(1):474. doi:10.1186/s13046-019-1442-2
   PubMed Web of Science ®Google Scholar
• Brandon EFA, Sparidans RW, Meijerman I, Manzanares I, Beijnen JH, Schellens JHM. In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug. Invest New Drugs. 2004;22(3):241–251. doi:10.1023/B:DRUG.0000026250.34645.7f
   PubMed Web of Science ®Google Scholar
• Kamdem LK, Flockhart DA, Desta Z. In vitro cytochrome P450-mediated metabolism of exemestane. Drug Metab Dispos. 2011;39(1):98–105. doi:10.1124/dmd.110.032276
   PubMed Web of Science ®Google Scholar
• Chen H, Shen Z-Y, Xu W, et al. Expression of P450 and nuclear receptors in normal and end-stage Chinese livers. World J Gastroenterol. 2014;20(26):8681–8690. doi:10.3748/wjg.v20.i26.8681
   PubMed Web of Science ®Google Scholar
• Guengerich FP. Cytochrome P450 enzymes as drug targets in human disease. Drug Metab Dispos. 2024;52(6):493–497. doi:10.1124/dmd.123.001431
   PubMed Web of Science ®Google Scholar
• Yang F, Hilakivi-Clarke L, Shaha A, et al. Metabolic reprogramming and its clinical implication for liver cancer. Hepatology. 2023;78(5):1602–1624. doi:10.1097/HEP.0000000000000005
   PubMed Web of Science ®Google Scholar
• Ishijima N, Kanki K, Shimizu H, Shiota G. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib. Cancer Sci. 2015;106(5):567–575. doi:10.1111/cas.12633
   PubMed Web of Science ®Google Scholar
• Fang Y, Zhan Y, Xie Y, et al. Integration of glucose and cardiolipin anabolism confers radiation resistance of HCC. Hepatology. 2022;75(6):1386–1401. doi:10.1002/hep.32177
   PubMed Web of Science ®Google Scholar
• Xu J, Ji L, Ruan Y, et al. UBQLN1 mediates sorafenib resistance through regulating mitochondrial biogenesis and ROS homeostasis by targeting PGC1β in hepatocellular carcinoma. Signal Transduct Target Ther. 2021;6(1):190. doi:10.1038/s41392-021-00594-4
   PubMed Web of Science ®Google Scholar
• Bergamini C, Leoni I, Rizzardi N, et al. MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma. J Exp Clin Cancer Res. 2023;42(1):145. doi:10.1186/s13046-023-02718-w
   PubMed Web of Science ®Google Scholar
• Holmstrã¶m P, Gã¥fvels M, Eriksson LC, et al. Expression of iron regulatory genes in a rat model of hepatocellular carcinoma. Liver Int. 2006;26(8):976–985. doi:10.1111/j.1478-3231.2006.01316.x
   PubMed Web of Science ®Google Scholar
• Gao J, Chen J, Kramer M, Tsukamoto H, Zhang A-S, Enns CA. Interaction of the hereditary hemochromatosis protein HFE with transferrin receptor 2 is required for transferrin-induced hepcidin expression. Cell Metab. 2009;9(3):217–227. doi:10.1016/j.cmet.2009.01.010
   PubMed Web of Science ®Google Scholar
• Tseng -H-H, Chang J-G, Hwang Y-H, Yeh K-T, Chen Y-L, H-s Y. Expression of hepcidin and other iron-regulatory genes in human hepatocellular carcinoma and its clinical implications. J Cancer Res Clin Oncol. 2009;135(10):1413–1420. doi:10.1007/s00432-009-0585-5
   PubMed Web of Science ®Google Scholar
• Hao S-H, X-d M, Xu L, et al. Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma. Drug Resist Updat. 2024;73:101052. doi:10.1016/j.drup.2024.101052
   PubMed Web of Science ®Google Scholar
• Kim YW, Lee SM, Shin SM, et al. Efficacy of sauchinone as a novel AMPK-activating lignan for preventing iron-induced oxidative stress and liver injury. Free Radic Biol Med. 2009;47(7):1082–1092. doi:10.1016/j.freeradbiomed.2009.07.018
   PubMed Web of Science ®Google Scholar
• Saito Y, Yin D, Kubota N, et al. A therapeutically targetable TAZ-TEAD2 pathway drives the growth of hepatocellular carcinoma via ANLN and KIF23. Gastroenterology. 2023;164(7):1279–1292. doi:10.1053/j.gastro.2023.02.043
   PubMed Web of Science ®Google Scholar
• Qi R, Bai Y, Li K, et al. Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs. Drug Resist Updat. 2023;68:100960. doi:10.1016/j.drup.2023.100960
   PubMed Web of Science ®Google Scholar
• Yang Y, Gu H, Zhang K, et al. Exosomal ACADM sensitizes gemcitabine-resistance through modulating fatty acid metabolism and ferroptosis in pancreatic cancer. BMC Cancer. 2023;23(1):789. doi:10.1186/s12885-023-11239-w
   PubMed Web of Science ®Google Scholar
• Qu X, Liu B, Wang L, et al. Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer. Drug Resist Updat. 2023;68:100936. doi:10.1016/j.drup.2023.100936
   PubMed Web of Science ®Google Scholar
• Kang X, Huo Y, Jia S, et al. Silenced LINC01134 enhances oxaliplatin sensitivity by facilitating ferroptosis through GPX4 in hepatocarcinoma. Front Oncol. 2022;12:939605. doi:10.3389/fonc.2022.939605
   PubMed Web of Science ®Google Scholar
• Zhan M, Ding Y, Huang S, et al. Lysyl oxidase-like 3 restrains mitochondrial ferroptosis to promote liver cancer chemoresistance by stabilizing dihydroorotate dehydrogenase. Nat Commun. 2023;14(1):3123. doi:10.1038/s41467-023-38753-6
   PubMed Web of Science ®Google Scholar
• Hu W, Zhou C, Jing Q, et al. FTH promotes the proliferation and renders the HCC cells specifically resist to ferroptosis by maintaining iron homeostasis. Cancer Cell Int. 2021;21(1):709. doi:10.1186/s12935-021-02420-x
   PubMed Web of Science ®Google Scholar
• Liu L, Lv Z, Wang M, Zhang D, Liu D, Zhu F. HBV enhances sorafenib resistance in hepatocellular carcinoma by reducing ferroptosis via SRSF2-mediated abnormal PCLAF splicing. Int J Mol Sci. 2023;24(4):3263.
   PubMed Web of Science ®Google Scholar
• Zhou Q-M, Y-f L, Zhou J-P, et al. Self-amplification of oxidative stress with tumour microenvironment-activatable iron-doped nanoplatform for targeting hepatocellular carcinoma synergistic cascade therapy and diagnosis. J Nanobiotechnology. 2021;19(1):361. doi:10.1186/s12951-021-01102-0
   PubMed Web of Science ®Google Scholar
• Corti A, Dominici S, Piaggi S, Pompella A. Enhancement of ferroptosis by boric acid and its potential use as chemosensitizer in anticancer chemotherapy. Biofactors. 2023;49(2):405–414. doi:10.1002/biof.1919
   PubMed Web of Science ®Google Scholar
• Wei W, Lu Y, Hu Q, et al. Synergistic antitumor efficacy of gemcitabine and cisplatin to induce ferroptosis in pancreatic ductal adenocarcinoma via Sp1-SAT1-polyamine metabolism pathway. Cell Oncol. 2023;47(1):321–341.
   Web of Science ®Google Scholar
• Zeng Y, Jiang H, Zhang X, et al. Canagliflozin reduces chemoresistance in hepatocellular carcinoma through PKM2-c-Myc complex-mediated glutamine starvation. Free Radic Biol Med. 2023;208:571–586. doi:10.1016/j.freeradbiomed.2023.09.006
   PubMed Web of Science ®Google Scholar
• Huang A, Yang X-R, Chung W-Y, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):146. doi:10.1038/s41392-020-00264-x
   PubMed Web of Science ®Google Scholar
• Yau T, Park J-W, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, Phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi:10.1016/S1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Zhu Y-J, Zheng B, Wang H-Y, Chen L. New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin. 2017;38(5):614–622. doi:10.1038/aps.2017.5
   PubMed Web of Science ®Google Scholar
• Liu M-R, Shi C, Song Q-Y, et al. Sorafenib induces ferroptosis by promoting TRIM54-mediated FSP1 ubiquitination and degradation in hepatocellular carcinoma. Hepatol Commun. 2023;7(10). doi:10.1097/HC9.0000000000000246
   Web of Science ®Google Scholar
• Sun J, Zhou C, Zhao Y, et al. Quiescin sulfhydryl oxidase 1 promotes sorafenib-induced ferroptosis in hepatocellular carcinoma by driving EGFR endosomal trafficking and inhibiting NRF2 activation. Redox Biol. 2021;41:101942. doi:10.1016/j.redox.2021.101942
   PubMed Web of Science ®Google Scholar
• Elkateb AS, Nofal S, Ali SA, Atya HB. Camptothecin sensitizes hepatocellular carcinoma cells to sorafenib- induced ferroptosis via suppression of Nrf2. Inflammation. 2023;46(4):1493–1511. doi:10.1007/s10753-023-01823-4
   PubMed Web of Science ®Google Scholar
• Iseda N, Itoh S, Yoshizumi T, et al. Impact of nuclear factor erythroid 2-related factor 2 in hepatocellular carcinoma: cancer metabolism and immune status. Hepatol Commun. 2022;6(4):665–678. doi:10.1002/hep4.1838
   PubMed Web of Science ®Google Scholar
• Sun X, Ou Z, Chen R, et al. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells. Hepatology. 2016;63(1):173–184. doi:10.1002/hep.28251
   PubMed Web of Science ®Google Scholar
• Sun X, Niu X, Chen R, et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology. 2016;64(2):488–500. doi:10.1002/hep.28574
   PubMed Web of Science ®Google Scholar
• Ding Z, Pan Y, Shang T, et al. URI alleviates tyrosine kinase inhibitors-induced ferroptosis by reprogramming lipid metabolism in p53 wild-type liver cancers. Nat Commun. 2023;14(1):6269. doi:10.1038/s41467-023-41852-z
   PubMed Web of Science ®Google Scholar
• Shi Z, Li Z, Jin B, et al. Loss of LncRNA DUXAP8 synergistically enhanced sorafenib induced ferroptosis in hepatocellular carcinoma via SLC7A11 de-palmitoylation. Clin Transl Med. 2023;13(6):e1300. doi:10.1002/ctm2.1300
   PubMed Web of Science ®Google Scholar
• Zhang L, X-m L, Shi X-H, et al. Sorafenib triggers ferroptosis via inhibition of HBXIP/SCD axis in hepatocellular carcinoma. Acta Pharmacol Sin. 2023;44(3):622–634. doi:10.1038/s41401-022-00981-9
   PubMed Web of Science ®Google Scholar
• Hu X, He Y, Han Z, et al. PNO1 inhibits autophagy-mediated ferroptosis by GSH metabolic reprogramming in hepatocellular carcinoma. Cell Death Dis. 2022;13(11):1010. doi:10.1038/s41419-022-05448-7
   PubMed Web of Science ®Google Scholar
• Xiao Y, Xu Z, Cheng Y, et al. Fe3+-binding transferrin nanovesicles encapsulating sorafenib induce ferroptosis in hepatocellular carcinoma. Biomater Res. 2023;27(1):63. doi:10.1186/s40824-023-00401-x
   PubMedGoogle Scholar
• Ren X, Li Y, Zhou Y, et al. Overcoming the compensatory elevation of NRF2 renders hepatocellular carcinoma cells more vulnerable to disulfiram/copper-induced ferroptosis. Redox Biol. 2021;46:102122. doi:10.1016/j.redox.2021.102122
   PubMed Web of Science ®Google Scholar
• Wang Q, Bin C, Xue Q, et al. GSTZ1 sensitizes hepatocellular carcinoma cells to sorafenib-induced ferroptosis via inhibition of NRF2/GPX4 axis. Cell Death Dis. 2021;12(5):426. doi:10.1038/s41419-021-03718-4
   PubMed Web of Science ®Google Scholar
• Lai Y, Lu N, Luo S, Wang H, Zhang P. A photoactivated sorafenib-Ruthenium(II) prodrug for resistant hepatocellular carcinoma therapy through ferroptosis and purine metabolism disruption. J Med Chem. 2022;65(19):13041–13051. doi:10.1021/acs.jmedchem.2c00880
   PubMed Web of Science ®Google Scholar
• Tang H, Chen D, Li C, et al. Dual GSH-exhausting sorafenib loaded manganese-silica nanodrugs for inducing the ferroptosis of hepatocellular carcinoma cells. Int J Pharm. 2019;572:118782. doi:10.1016/j.ijpharm.2019.118782
   PubMed Web of Science ®Google Scholar
• Kim D-H, Kim M-J, Kim N-Y, et al. DN200434, an orally available inverse agonist of estrogen-related receptor γ, induces ferroptosis in sorafenib-resistant hepatocellular carcinoma. BMB Rep. 2022;55(11):547–552. doi:10.5483/BMBRep.2022.55.11.089
   PubMed Web of Science ®Google Scholar
• Iseda N, Itoh S, Toshida K, et al. Ferroptosis is induced by lenvatinib through fibroblast growth factor receptor-4 inhibition in hepatocellular carcinoma. Cancer Sci. 2022;113(7):2272–2287. doi:10.1111/cas.15378
   PubMed Web of Science ®Google Scholar
• Song Z, Zhang Y, Luo W, et al. HAND2-AS1 promotes ferroptosis to reverse lenvatinib resistance in hepatocellular carcinoma by TLR4/NOX2/DUOX2 Axis. Curr Cancer Drug Targets. 2024;24. doi:10.2174/0115680096279597240219055135
   Google Scholar
• Zhang N, Yang X, Piao M, et al. Biomarkers and prognostic factors of PD-1/PD-L1 inhibitor-based therapy in patients with advanced hepatocellular carcinoma. Biomark Res. 2024;12(1):26. doi:10.1186/s40364-023-00535-z
   PubMed Web of Science ®Google Scholar
• Itoh S, Yoshizumi T, Yugawa K, et al. Impact of immune response on outcomes in hepatocellular carcinoma: association with vascular formation. Hepatology. 2020;72(6):1987–1999. doi:10.1002/hep.31206
   PubMed Web of Science ®Google Scholar
• Zheng Y, Wang Y, Lu Z, et al. PGAM1 inhibition promotes HCC ferroptosis and synergizes with anti-PD-1 immunotherapy. Adv Sci. 2023;10(29):e2301928. doi:10.1002/advs.202301928
   Web of Science ®Google Scholar
• Qiu Y, Wu Z, Chen Y, et al. Nano ultrasound contrast agent for synergistic chemo-photothermal therapy and enhanced immunotherapy against liver cancer and metastasis. Adv Sci. 2023;10(21):e2300878. doi:10.1002/advs.202300878
   Web of Science ®Google Scholar
• Zhang D, Man D, Lu J, et al. Mitochondrial TSPO promotes hepatocellular carcinoma progression through ferroptosis inhibition and immune evasion. Adv Sci. 2023;10(15):e2206669.
   Web of Science ®Google Scholar
• Conche C, Finkelmeier F, Peå¡iä‡ M, et al. Combining ferroptosis induction with MDSC blockade renders primary tumours and metastases in liver sensitive to immune checkpoint blockade. Gut. 2023;72(9):1774–1782. doi:10.1136/gutjnl-2022-327909
   PubMed Web of Science ®Google Scholar
• Tang B, Zhu J, Wang Y, et al. Targeted xCT-mediated ferroptosis and protumoral polarization of macrophages is effective against HCC and enhances the efficacy of the anti-PD-1/L1 response. Adv Sci. 2023;10(2):e2203973. doi:10.1002/advs.202203973
   Web of Science ®Google Scholar
• Hao X, Zheng Z, Liu H, et al. Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing. Redox Biol. 2022;56:102463. doi:10.1016/j.redox.2022.102463
   PubMed Web of Science ®Google Scholar
• Li Y, Yang W, Zheng Y, et al. Targeting fatty acid synthase modulates sensitivity of hepatocellular carcinoma to sorafenib via ferroptosis. J Exp Clin Cancer Res. 2023;42(1):6. doi:10.1186/s13046-022-02567-z
   PubMed Web of Science ®Google Scholar
• Yang M, Wu X, Hu J, et al. COMMD10 inhibits HIF1α/CP loop to enhance ferroptosis and radiosensitivity by disrupting Cu-Fe balance in hepatocellular carcinoma. J Hepatol. 2022;76(5):1138–1150. doi:10.1016/j.jhep.2022.01.009
   PubMed Web of Science ®Google Scholar
• Dang W, Chen W-C, Ju E, et al. 3D printed hydrogel scaffolds combining glutathione depletion-induced ferroptosis and photothermia-augmented chemodynamic therapy for efficiently inhibiting postoperative tumor recurrence. J Nanobiotechnology. 2022;20(1):266. doi:10.1186/s12951-022-01454-1
   PubMed Web of Science ®Google Scholar
• Chen Q, Zheng W, Guan J, et al. SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. Cell Death Differ. 2023;30(1):137–151. doi:10.1038/s41418-022-01051-7
   PubMed Web of Science ®Google Scholar